Menu
Menu
SOPHiA GENETICS will be attending the International Society for Liquid Biopsy Annual Meeting (ISLB) in Madrid, Spain! We look forward to connecting with leaders and innovators to discuss the evolving role of data in shaping the future of healthcare. Meet us at Booth #21.
More information is coming soon!
SOPHiA GENETICS is heading to the European Society for Medical Oncology Congress (ESMO) 2026 in Madrid, Spain. Meet our team at Booth #104 to learn how we are helping advance precision medicine through intelligent analytics and collaborative innovation.
More updates on our participation and activities will be announced soon!
Join SOPHiA GENETICS at the European Congress of Pathology (ECP) 2026 in Stockholm, Sweden. We are excited to engage with the pathology community and share how our technology helps transform complex data into practical insights.
Visit our page again shortly for more information!
SOPHiA GENETICS will be at the Association for Molecular Pathology Europe Congress (AMP Europe) 2026 in Tallinn, Estonia. We are looking forward to discussing how we support laboratories and healthcare institutions with scalable, data-driven solutions.
Additional details will be available soon!
About the Sumit
The decisions made in the next few years will define the trajectory of human health for decades to come. SOPHiA GENETICS brings together the pioneers making those decisions — clinicians, researchers, and biopharma leaders who refuse to accept the status quo.
Join us September 22–23, 2026 in Nashville for two immersive days at the intersection of AI, multimodal data, and precision medicine. Where bold ideas meet the real-world science to make them possible.
ATTENDEE VOICES
“Huge thanks to SOPHiA GENETICS for organizing this impactful event and for the opportunity to network with so many passionate leaders driving innovation in AI and life science.” – 2025 SUMMIT ATTENDEE
Save the date. Register your interest. Be part of what’s next.
The SOPHiA GENETICS™ Global Precision Medicine Forum returns to Chicago! Join us on May 29th at 3:00 PM CST at The Metropolitan in Chicago, IL, for its 2026 edition.
Two years ago, SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center (MSK) started a liquid biopsy revolution that has since grown into a global shift in precision oncology access. This forum brings together the minds behind that shift to reflect on what was built, its real-world impact, and reveal what comes next.
Join Pharma and Biotech leaders, oncology KOLs, and diagnostic partners to explore The Liquid Biopsy Movement: From MSK to the World, and how it is reshaping the future of cancer care.
Across different sessions, the forum will explore:
Don't miss this unique opportunity and reserve your spot now!
Le invitamos a participar en este exclusivo encuentro que reunirá a expertos y líderes clínicos para explorar los avances más recientes en medicina de precisión y genómica aplicada.
El evento contará con la participación del Presidente de SOPHiA GENETICS, quien compartirá la visión global de la compañía, así como con especialistas que abordarán el impacto de NGS en hemato-oncología y las tendencias futuras del área.
Asimismo, el evento destacará experiencias reales de clientes que compartirán su práctica clínica utilizando la plataforma SOPHiA DDM™, ofreciendo una perspectiva concreta sobre su impacto en el diagnóstico y la toma de decisiones.
A continuación, encontrará la agenda preliminar del evento.
What: SOPHiA GENETICS Exclusive Networking event
Where: Savoy Hotel
Date: 21 de abril
Time: 19:00 - 22:00
19:00 – 19:30
Leading Innovation to Impact: SOPHiA GENETICS’ Global Vision
Ross Muken, President, SOPHiA GENETICS
19:30 – 20:00
Panel NGS para LLC: implementación y validación analítica.
Mauro García-Montenegro
Jefe Anatomia Patologia, Argenetics
20:00 - 20:30
Paneles de genes mediante NGS: Transformando el estudio de las neoplasias mieloides
Andrea Bender, Especialista en Bioquímica Clínica Laboratorio de Especialidades Bioquimicas (LEB)
20:30 – 21:00
What’s Next in Hemato-Oncology Genomics
Bruno Piovezan, Subject Matter Expert LATAM, SOPHiA GENETICS
21:00 – 22:00
Cocktails & Networking
Discover how SOPHiA DDM™ enables accurate analysis across multiple disease areas – from oncology to inherited disorders
Discuss the future of research and healthcare institutions to harness NGS data for quick, robust, and actionable insights, guiding best decisions.
Connect with your peers and enjoy a networking environment with your peers and users of SOPHiA DDM™ Platform
El GENOMiCS INSIGHTS Day Bogotá se llevará a cabo el próximo 23 de abril, en el Hotel W Bogotá.
Este encuentro reunirá a expertos, líderes clínicos y profesionales del área de la genómica para explorar los avances más recientes en medicina de precisión y el impacto creciente de las tecnologías genómicas en la práctica clínica.
Durante la jornada abordaremos temas clave como la visión global de innovación de SOPHiA GENETICS, las nuevas posibilidades clínicas de la biopsia líquida, experiencias reales de implementación en la práctica clínica con la plataforma SOPHiA DDM™, y nuevas oportunidades para ampliar el análisis genómico mediante exomas optimizados.
Este espacio también busca fomentar el intercambio de experiencias y la conversación entre profesionales del sector, promoviendo el avance de la medicina genómica en la región.
A continuación, encontrará la agenda preliminar del evento.
What: SOPHiA GENETICS Exclusive Networking event
Where: Hotel W Bogotá
Date: 23 de abril
Time: 16:00 - 19:00
16:00 – 16:30
De la innovación al impacto: la visión global de SOPHiA GENETICS.
Ross Muken, President, SOPHiA GENETICS
16:30 – 17:00
Expandiendo las posibilidades clínicas con las soluciones de biopsia líquida de SOPHiA GENETICS.
Luna Rodriguez, Subject Matter Expert LATAM, SOPHiA GENETICS
17:00 - 17:30
Biopsia líquida en la práctica clínica: experiencia real con la plataforma SOPHiA DDM™.
July Katherine Rodriguez Ariza, Directora científica, FICMAC
17:30 – 18:00
Exomas optimizados: una nueva oportunidad para expandir el análisis genómico.
Gabriela Acosta, Sales Executive, LATAM SOPHiA GENETICS
Discover how SOPHiA DDM™ enables accurate analysis across multiple disease areas – from oncology to inherited disorders
Discuss the future of research and healthcare institutions to harness NGS data for quick, robust, and actionable insights, guiding best decisions.
Connect with your peers and enjoy a networking environment with your peers and users of SOPHiA DDM™ Platform
Join SOPHiA GENETICS at the European Human Genetics Conference (ESHG) 2026 in Gothenburg, Sweden! Our team of experts will be at Booth #214 to engage with partners and peers across the genomics community.
Stay tuned for information and session updates!
SOPHiA GENETICS is thrilled to return for ACMG 2026! Visit us at booth #1007 to learn more about our SOPHiA DDM™ and Alamut™ Visual Plus platforms for rare and inherited diseases.
Discover more about our newly launched extended pharmacogenomics (PGx) application, which covers HLA and mitochrondrial regions, with dedicated analytical modules that call variants from SNVs and CNvs to star alleles and CYP2D6/CVP2D7 gene conversion.
Learn more about SOPHiA DDM™ for whole genome sequencing and how our enhanced exome solutions detect challenging variants relevant for carrier screening, hereditary cancer, and PGx in one comprehensive application.
Exhibit Theater 1
Thursday March 12
12:30pm-1:00pm
Future-Ready Genomics: Real World Implementation and Validation from Hereditary Cancer to WGS
Dr. Francisco Perez Blanco, PhD, Chief of Molecular Diagnostics and Biometrics Laboratory, Clinical Alemana de Santiago
Sevana Yaghoubian, MSc - Senior Director of Product Management, SOPHiA GENETICS.
Join this talk to hear real-world clinical experience, implementation, and validation insights, and performance data from SOPHiA DDM™ germline NGS applications, covering hereditary cancer, enhanced exomes, whole-genome sequencing, and pharmacogenomics.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.